立体定向体部放疗后肝细胞癌高强度聚焦超声治疗的可行性:初步经验
本研究初步观察了立体定向体部放疗(SBRT)后肝细胞癌(HCC)患者接受高强度聚焦超声(HIFU)消融的安全性和效果,20例患者共24个局部残留病灶接受HIFU消融。HIFU后1周外周血细胞计数和血清生化未见显著差异,无严重不良反应;17个(70.8%)残留病灶完全消融,7个部分消融,平均消融比例75.8%±18.2%。中位生存时间21个月,1年生存率76.2%。作者认为HIFU可安全有效地消融SBRT后残留HCC,可能是SBRT后局部残留HCC患者的一种可行选择。
要点
- SBRT后HCC局部残留灶行HIFU消融,17/24个(70.8%)达完全消融,平均消融比例75.8%±18.2%。
- HIFU后1周外周血细胞计数和血清生化与术前无显著差异,未见HIFU相关严重不良反应。
- 中位随访19.3±18.0个月,中位生存时间21个月,1年生存率76.2%。
核心结论
- 作者认为HIFU可安全有效地消融SBRT后残留HCC,可能是SBRT后局部残留HCC患者的一种可行选择。
研究设计与样本
- 初步临床观察,20例曾接受SBRT的HCC患者共24个局部残留病灶接受HIFU消融;HIFU前及HIFU后1周观察外周血细胞计数和血清生化变化,HIFU前及HIFU后2周行对比增强MRI评估消融效果;所有患者接受随访,平均随访时间19.3±18.0个月。
诊断标准与关键数值
- 17个残留病灶(70.8%)达完全消融,7个部分消融,平均消融比例75.8%±18.2%;中位生存时间21个月,1年生存率76.2%。
临床应用与阅片要点
- 作者认为HIFU可安全有效地消融SBRT后残留HCC,可能是SBRT后局部残留HCC患者的一种可行选择;HIFU后2周行对比增强MRI评估消融效果。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The purpose of this initial clinical observation was to investigate the safety and effect of high-intensity focused ultrasound (HIFU) for patients with hepatocellular carcinoma (HCC) after stereotactic body radiation therapy (SBRT). Twenty patients who had been treated with SBRT, with 24 local residuals, received HIFU ablation. The changes of periphery blood cell count and serum biochemistry were observed before HIFU and 1 week after. Contrast-enhanced magnetic resonance imaging before HIFU and 2 weeks after was performed to assess the effect of HIFU. All patients received follow-up. The mean ± standard deviation follow-up time was 19.3 ± 18.0 mo. The median survival time and 1-y survival rate were 21 mo and 76.2%. Seventeen residual lesions (70.8%) received complete ablation and seven received partial ablation, with a mean ablation ratio of 75.8% ± 18.2%. No significant differences were found in periphery blood cell counts or serum biochemistry 1 week after HIFU compared with before HIFU. No severe adverse reactions related to HIFU were observed. Thus, we believe that HIFU can safely and effectively ablate residual HCC after SBRT, which may be a feasible option for patients with HCC who have local residuals after SBRT.
引用
- Jin C, Yang W, Ran L, et al. Feasibility of High-Intensity Focused Ultrasound for Hepatocellular Carcinoma after Stereotactic Body Radiation Therapy: Initial Experience. Ultrasound Med Biol. 2020. PMID: 32747074. doi:10.1016/j.ultrasmedbio.2020.06.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。